The Boston Globe takes a look at Knome, the consumer genomic company that sequences its customers' genomes while rounding up the challenges facing the field -- those cease-and-desist letters and the debate over medical relevance. The writer, Scott Kirsner, asks Raju Kucherlapati and David Altshuler if they'd get their genomes sequenced. Kucherlapati already had his looked at by Navigenics -- it confirmed problems he thought would be there -- and Altshuler, who turned that test down, says that a good family history also does the trick.
Premium Trial: